Henlius Seeks To Add RA Indication To Chinese Rituximab
HLX01 Biosimilar Was First Approved In China Under New Pathway
Executive Summary
Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.